Vical Stockholders Approve Reverse Stock Split and Merger with Brickell
30 août 2019 11h54 HE
|
Vical Incorporated
• Merger Transaction Expected to Close August 31, 2019 SAN DIEGO, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Vical Incorporated (“Vical”) (Nasdaq:VICL) announced that its stockholders voted to approve the...
Vical and Brickell Announce Merger Agreement
03 juin 2019 03h00 HE
|
Vical Incorporated
Combined Company Well-Capitalized with Approximately $35 Million in Cash and up to $25 Million in Near-Term R&D FundingPivotal Phase 3 Clinical Trials for Brickell’s Lead Product Candidate,...
Vical to Discontinue Clinical Development of VL-2397 as it Considers Near Term Strategic Alternatives
19 févr. 2019 17h45 HE
|
Vical Incorporated
SAN DIEGO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that it has decided to discontinue the Phase 2 clinical trial of VL‑2397 that was initiated in the first...
Vical Reports Third Quarter 2018 Financial and Operational Results
29 oct. 2018 06h30 HE
|
Vical Incorporated
SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months ended September 30, 2018. Net loss for the third quarter of 2018...
Vical to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
23 août 2018 08h00 HE
|
Vical Incorporated
SAN DIEGO, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on...
Vical Reports Second Quarter 2018 Financial and Operational Results
07 août 2018 06h30 HE
|
Vical Incorporated
SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months ended June 30, 2018. Net loss for the second quarter of 2018 was...
Vical Announces Review of Potential Strategic Transactions
19 juil. 2018 06h00 HE
|
Vical Incorporated
SAN DIEGO, July 19, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that its Board of Directors plans to explore a range of strategic options to enhance shareholder value....
Vical Reports Phase 2 Trial of HSV-2 Therapeutic Vaccine Did Not Meet Primary Endpoint
11 juin 2018 06h00 HE
|
Vical Incorporated
SAN DIEGO, June 11, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced top-line results from a randomized, double-blind, placebo-controlled, Phase 2 clinical study of its...
Vical Reports First Quarter 2018 Financial and Operational Results
03 mai 2018 06h30 HE
|
Vical Incorporated
SAN DIEGO, May 03, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months ended March 31, 2018. Net loss for the first quarter of 2018 was...
Vical Announces News Release and Conference Call Schedule for First Quarter 2018 Financial Results
26 avr. 2018 16h05 HE
|
Vical Incorporated
SAN DIEGO, April 26, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended March 31, 2018, before the...